Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells

Molecular Pharmacology

Volumn 70, Issue 6, 2006, Pages 1965-1973

  Pei, Xin Yan ^a   Li, Weiqun ^a   Dai, Yun ^a   Dent, Paul ^b   Grant, Steven ^a,b,c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 7 HYDROXYSTAUROSPORINE; CHECKPOINT KINASE 1; CYCLIN DEPENDENT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LETHALITY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

APOPTOSIS; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLATION; PROTEIN KINASES; RNA INTERFERENCE; STAUROSPORINE;

EID: 33751080139     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.028373     Document Type: Article

References (39)

1. 2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem 274:2732-2742.
2. Allan LA, Morrice N, Brady S, Magee G, Pathak S, and Clarke PR (2003) Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. Nat Cell Biol 5:647-654.
3. Byrd JC, Shinn C, Willis CR, Flinn IW, Lehman T, Sausville E, Lucas D, and Grever MR (2001) UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol 29:703-708.
4. Chang L and Karin M (2001) Mammalian MAP kinase signalling cascades. Nature (Lond) 410:37-40.
5. Cross DA and Smythe C (1998) PD 98059 prevents establishment of the spindle assembly checkpoint and inhibits the G2-M transition in meiotic but not mitotic cell cycles in Xenopus. Exp Cell Res 241:12-22.
6. Dai Y, Landowski TH, Rosen ST, Dent P, and Grant S (2002) Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 100:3333-3343.
7. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, and Grant S (2005) Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105: 1706-1716.
8. Dai Y, Yu C, Singh V, Tang L, Wang Z, McInistry R, Dent P, and Grant S (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61:5106-5115.
9. Dangi S and Shapiro P (2005) Cdc2-mediated inhibition of epidermal growth factor activation of the extracellular signal-regulated kinase pathway during mitosis. J Biol Chem 280:24524-24531.
10. Dash BC and El-Deiry WS (2005) Phosphorylation of p21 in G2/M promotes cyclin B-Cdc2 kinase activity. Mol Cell Biol 25:3364-3387.
11. Facchinetti MM, De Siervi A, Toskos D, and Senderowicz AM (2004) UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res 64:3629-3637.
12. Furukawa Y, Iwase S, Kikuchi J, Terui Y, Nakamura M, Yamada H, Kano Y, and Matsuda M (2000) Phosphorylation of Bcl-2 protein by CDC2 kinase during G2/M phases and its role in cell cycle regulation. J Biol Chem 275:21661-21667.
13. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, and Piwnica-Worms H (2000) The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275:5600-5605.
14. Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, et al. (2005) Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther 4:1275-1284.
15. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, Pond GR, Dancey JE, and Hirte HW (2006) Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 17:334-340.
16. Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, and Li W (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96:3560-3568.
17. Kastan MB and Bartek J (2004) Cell-cycle checkpoints and cancer. Nature (Lond) 432:316-323.
18. Kohn EA, Ruth ND, Brown MK, Livingstone M, and Eastman A (2002) Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 277:26553-26564.
19. Konishi Y, Lehtinen M, Donovan N, and Bonni A (2002) Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol Cell 9:1005-1016.
20. McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, and Dent P (2002) Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biol Ther 1:243-253.
21. Moller C, Alfredsson J, Engstrom M, Wootz H, Xiang Z, Lennartsson J, Jonsson JI, and Nilsson G (2005) Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 106:1330-1336.
22. Niida H and Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis 21:3-9.
23. Pan J and Yeung SC (2005) Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res 65:9109-9112.
24. Pei XY, Dai Y, Rahmani M, Li W, Dent P, and Grant S (2005) The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 11:4589-4600.
25. Racke FK, Lewandowska K, Goueli S, and Goldfarb AN (1997) Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem 272:23366-23370.
26. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, and Plunkett W (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107:2517-2524.
27. Sato S, Fujita N, and Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21:1727-1738.
28. L by the MAPK/Erk kinase. J Biol Chem 274:31108-31113.
29. Shao RG, Shimizu T, and Pommier Y (1997) 7-Hydroxystaurosporine (UCN-01) induces apoptosis in human colon carcinoma and leukemia cells independently of p53. Exp Cell Res 234:388-397.
30. Shimizu T, O'Connor PM, Kohn KW, and Pommier Y (1995) Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res 55:228-231.
31. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, and McCubrey JA (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18:189-218.
32. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, Helleday T, Sehested M, Lukas J, and Bartek J (2005) Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25:3553-3562.
33. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T, Ikeda K, Nakayama K, Nakanishi M, and Nakayama K (2000) Aberrant cell cycle checkpoint function and early embryonic death in Chk1 (-/-) mice. Genes Dev 14:1439-1447.
34. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA (1995) Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 6:927-936.
35. Yan Y, Haas JP, Kim M, Sgagias MK, and Cowan KH (2002) BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J Biol Chem 277:33422-33430.
36. Yan Y, Spieker RS, Kim M, Stoeger SM, and Cowan KH (2005) BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 24:3285-3296.
37. Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, and Brody LC (2002) BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285-289.
38. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 62:5743-5748.
39. Zhang J, Choi Y, Mavromatis B, Lichtenstein A, and Li W (2003) Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene 22: 6289-6295.